Transaction · 0000921895-26-002590

Bvf Partners L P/Il

BVF PARTNERS L P/IL, DIR, reported a transaction classified as grant at IMMUNIC, INC. involving 25370.000000 shares for an estimated $0.00. Reported holdings after the transaction were 25370.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
IMUXIMMUNIC, INC.
Trade date
Sep 16, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded25.3k$0.00 per share
Holdings after25.3kIndirect · See footnote
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

IMUX price since this filing

Daily closing prices, with the filing date and available return windows
IMUX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0000921895-26-002590
Stock Option
Transaction date
Sep 16, 2026
Filed Sep 18, 2026, 11:45 PM · 2d delay
Shares
25,370 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
25,370 sh
Indirect · See footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther Yes
Footnotes & amended
  1. F1

    This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("P…

  2. F2

    Reflects a one-for-ten reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 27, 2026 (the "Stock Split").

  3. F3

    Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to b…

  4. F4

    Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed…

  5. F5

    Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investme…

  6. F6

    The option vests in monthly increments over a period of one year from the grant date.

  7. F7

    Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and R. Thorvald Nagel, who serves on t…

Original filing · 0000921895-26-002590
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

IMUX